AlphaMark Advisors LLC Has $93,000 Stake in Novartis AG (NYSE:NVS)

AlphaMark Advisors LLC boosted its holdings in shares of Novartis AG (NYSE:NVS) by 37.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 965 shares of the company’s stock after buying an additional 265 shares during the period. AlphaMark Advisors LLC’s holdings in Novartis were worth $93,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of NVS. Wellington Management Group LLP boosted its stake in Novartis by 1.2% in the 4th quarter. Wellington Management Group LLP now owns 4,746,599 shares of the company’s stock valued at $479,264,000 after buying an additional 54,683 shares in the last quarter. Fisher Asset Management LLC grew its holdings in shares of Novartis by 2.4% in the 4th quarter. Fisher Asset Management LLC now owns 1,442,003 shares of the company’s stock worth $145,599,000 after purchasing an additional 33,791 shares during the last quarter. Natixis Advisors L.P. increased its position in shares of Novartis by 0.4% during the 4th quarter. Natixis Advisors L.P. now owns 931,127 shares of the company’s stock worth $94,014,000 after purchasing an additional 3,270 shares in the last quarter. Chevy Chase Trust Holdings LLC lifted its holdings in Novartis by 11.3% during the 4th quarter. Chevy Chase Trust Holdings LLC now owns 815,804 shares of the company’s stock valued at $82,372,000 after purchasing an additional 82,909 shares during the last quarter. Finally, Morningstar Investment Services LLC boosted its position in Novartis by 99.0% in the fourth quarter. Morningstar Investment Services LLC now owns 746,836 shares of the company’s stock valued at $74,661,000 after buying an additional 371,590 shares in the last quarter. Institutional investors and hedge funds own 13.12% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. The Goldman Sachs Group initiated coverage on shares of Novartis in a research note on Thursday, May 30th. They issued a “buy” rating and a $120.00 target price for the company. Barclays raised Novartis to a “strong sell” rating in a research note on Monday, June 24th. Finally, BMO Capital Markets raised their target price on Novartis from $114.00 to $116.00 and gave the company a “market perform” rating in a research note on Wednesday, April 24th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $116.67.

Novartis Trading Up 0.1 %

NVS stock traded up $0.08 during midday trading on Monday, hitting $106.54. 1,194,184 shares of the company’s stock were exchanged, compared to its average volume of 1,473,263. Novartis AG has a one year low of $92.19 and a one year high of $108.78. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.71 and a current ratio of 0.90. The company has a market cap of $217.77 billion, a PE ratio of 14.38, a price-to-earnings-growth ratio of 1.64 and a beta of 0.57. The stock’s fifty day moving average price is $102.22 and its 200-day moving average price is $101.22.

Novartis (NYSE:NVS) last announced its earnings results on Tuesday, April 23rd. The company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.73 by $0.07. Novartis had a net margin of 31.33% and a return on equity of 32.15%. The firm had revenue of $11.83 billion for the quarter, compared to the consensus estimate of $11.50 billion. Research analysts predict that Novartis AG will post 7.27 earnings per share for the current fiscal year.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.